Cooperative Genomic Lesions in HRAS-Mutant Cancers Predict Resistance to Farnesyltransferase Inhibitors.


Journal

Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035

Informations de publication

Date de publication:
14 Jul 2023
Historique:
pubmed: 28 7 2023
medline: 28 7 2023
entrez: 28 7 2023
Statut: epublish

Résumé

The clinical development of farnesyltransferase inhibitors (FTI) for

Identifiants

pubmed: 37503077
doi: 10.21203/rs.3.rs-3154719/v1
pmc: PMC10371077
pii:
doi:

Types de publication

Preprint

Langues

eng

Déclaration de conflit d'intérêts

Competing Interest Statement: No additional competing interests to disclose

Auteurs

Aradhya Nigam (A)

Memorial Sloan Kettering Cancer Center.

Gnana Krishnamoorthy (G)

Memorial Sloan Kettering Cancer Center.

Walid Chatila (W)

Memorial Sloan-Kettering Cancer Center.

Katherine Berman (K)

Memorial Sloan-Kettering Cancer Center.

Mahesh Saqcena (M)

Memorial Sloan-Kettering Cancer Center.

Henry Walch (H)

Memorial Sloan-Kettering Cancer Center.

Alan Ho (A)

Memorial Sloan-Kettering Cancer Center.

Nikolaus Schultz (N)

Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center.

James Fagin (J)

Memorial Sloan Kettering Cancer Center.

Brian Untch (B)

Memorial Sloan Kettering Cancer Center.

Classifications MeSH